Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Cervical cancer
Stage/Subtype:  recurrent cervical cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ME-344-002, NCI-2014-01013, NCT02100007
T-cell Receptor Gene Therapy Targeting HPV-16 E6 in Treating Patients with Metastatic, Recurrent, or Refractory HPV-Related Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0005, NCI-2014-02319, 1407-1331, 337514, P141607, RD-14-VIII-09, NCT02280811
Vaccine Therapy in Treating Patients with Persistent or Recurrent Cervical Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GOG-0265, NCI-2011-02671, CDR0000691288, NCT01266460
Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin after Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Refractory Human Papilloma Virus-Associated Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0116, NCI-2013-01524, 120116, 12C0116-H, 327146, P11943, NCT01585428
Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 5C-11-2, NCI-2012-01378, HS-11-00547, NCT01676818
Nivolumab in Treating Patients with Persistent, Recurrent, or Metastatic Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY002, NCI-2014-02021, PNRG-GY002_A01PAMDREVW01, NCT02257528
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Z-endoxifen Hydrochloride in Treating Patients with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0061, NCI-2013-01475, 110061, P10725, 8826, NCT01273168
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Treating Patients With Persistent or Recurrent Gynecological Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: CASE 8810, NCI-2012-00608, NCT01652794
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4190C00010, NCI-2014-02609, NCT02261220
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, P08407, NCT00924027
Ribavirin in Treating Patients with Recurrent or Metastatic HPV-Related Malignancies
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 14-211, NCI-2014-02540, NCT02308241
Start Over